Top 5 Forestry Stocks To Buy For 2015

By almost any measure, Stamps.com Inc. (NASDAQ:STMP) is a solid investment. Revenue and profits are on the rise, and are projected to grow again in 2014. Stamps.com has also developed a penchant for earnings beats. And, at a trailing P/E of 18.3 and a forward-looking P/E ratio of 15.7, it's not like STMP shares cost a relative fortune. Yet, STMP is starting to look like a major liability where it could hurt shareholders the most... on the chart.

Yes, it's an unpopular reality, and the prod for many-a-debate about how you can't predict a stock's future value based on its price history. Of course, you can't actually presume a stock's ever going to reflect a company's fundamentals, nor is there any guarantee a company will continue to produce solid growth in perpetuity... a couple of details the fundamentals crowd tends to gloss over. More than that, the fact is, while a chart history isn't a 100% perfect tool for predicting a chart's future, the fact is, you CAN get a pretty darn good feel for a stock's foreseeable future based on the chart, and it just so happens that Stamps.com shares have dropped a pretty good technical clue that investors may want to note.

Top 5 Gas Utility Stocks To Invest In 2016: Cell Therapeutics Inc (CTIC)

Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.

Pixuvri

As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.

OPAXIO

OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.

Tosedostat

In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.

Brostallicin

As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).

The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.

Advisors' Opinion:

• [By Bryan Murphy]

  If you're reading this, then odds are you already know that the last two weeks (not even a full two weeks) have been more fruitful for Cell Therapeutics Inc. (NASDAQ:CTIC) shareholders than the prior two years have been - the stock's up 28% since last Thursday. And, odds are you already know why. The question most of you are asking now is, can CTIC actually keep climbing at this pace, or even keep climbing at any pace? The answer is "yes", though floating that answer almost inherently requires a deeper explanation.

• [By Bryan Murphy]

  Like it or not, all good things must come to an end.... even for a red hot stock like Cell Therapeutics Inc. (NASDAQ:CTIC). Yes, CTIC is up 111% since the end of 2013, up 14% today alone, and it doesn't look like the bulls have any reason to slow down now. That's exactly why now's the time for current shareholders to be afraid, however - expect it when you least expect it.

• [By Sean Williams]

  Cell Therapeutics (NASDAQ: CTIC  )
  Certainly no discussion of companies with large accumulated deficits would be complete without discussing a biotechnology company. It's perfectly understandable to see a biotech, especially a clinical-stage one, run with an accumulated deficit, as it takes time and money to build up a drug pipeline. However, after multiple complete response letters (the equivalent of a rejection) by the Food and Drug Administration and years without an approved drug, Cell Therapeutics racked up an astounding $1.83 billion in accumulated deficits through the end of fiscal 2012. By comparison, that's nearly 56 times larger than its shareholder equity.�

Top 5 Forestry Stocks To Buy For 2015: Ross Stores Inc.(ROST)

Ross Stores, Inc., together with its subsidiaries, operates off-price retail apparel and home accessories stores under the Ross Dress for Less and dd?s DISCOUNTS brand names in the United States. Its Ross Dress for Less brand stores sell brand and designer apparel, accessories, footwear, and home fashions for the entire family at everyday savings of 20 to 60 percent off department and specialty store regular prices; and dd?s DISCOUNTS brand stores sell apparel, accessories, footwear, and home fashions for the entire family at everyday savings of 20 to 70 percent off moderate department and discount store regular prices. As of January 29, 2011, the company operated 1,055 stores, of which 988 were Ross Dress for Less brand stores in 27 states and Guam, and 67 were dd?s DISCOUNTS brand stores in 6 states. Its Ross Dress for Less brand stores primarily target middle income households and dd?s DISCOUNTS brand stores target moderate income households. Ross Stores, Inc. was found ed in 1957 and is headquartered in Pleasanton, California.

Advisors' Opinion:

• [By Tom Taulli]

  Competition: While TJX attempts to undercut more traditional retailers, it has plenty of competition in the deep-discount game, Ross Stores (ROST), Kohl’s (KSS) and Burlington Stores (BURL). TJX also must contend with big-box operators like Target (TGT). So far, TJX has been able to dig itself a niche and remain fairly differentiated, but it’s fair to point out the danger in slipping — in retail, customers always have plenty of alternatives.

Top 5 Forestry Stocks To Buy For 2015: Kid Brands Inc (KID)

Kid Brands, Inc., incorporated on June 1966, is a designer, importer, marketer and distributor of branded infant and juvenile consumer products. The Company through its wholly owned operating subsidiaries: Kids Line, LLC (Kids Line); LaJobi, Inc. (LaJobi); Sassy, Inc. (Sassy), and CoCaLo, Inc. (CoCaLo) designs and markets branded infant and juvenile products in a number of categories, including, among others: infant bedding and related nursery accessories and decor, nursery appliances, bath/spa products and diaper bags (Kids Line and CoCaLo); nursery furniture and related products (LaJobi), and developmental toys and feeding, bath and baby care items with features that address the various stages of an infant�� early years, including Kokopax line of baby gear (Sassy). In addition to its branded products, it also markets certain categories of products under various licenses, including Carter��, Disney, Graco and Serta.

The Company�� products are sold primarily to large, national retail accounts and independent retailers (including toy, specialty, food, drug, apparel and other retailers). The Company maintains relationships with international distributors to service certain retail customers in several foreign countries, as well as with several independent representatives to service select domestic and foreign retail customers. The Company�� infant and juvenile product line consists of approximately 7,400 products that principally focus on newborn to three year old children. It also caters to the age range between three through seven, including toddler bedding and beds, as well as kitchen products. Kids Line products, which are marketed primarily under the Kids Line, Carter�� and Disney brands, and CoCaLo products, which are marketed primarily under the CoCaLo Baby, CoCaLo Couture, and CoCaLo Naturals brands, each consist primarily of infant bedding and related nursery accessories and decor, such as blankets, rugs, mobiles, nightlights, hampers, lamps and wall art, as well as nurser! y appliances, diaper bags and spa/bath products. LaJobi products, which are marketed primarily under the Babi Italia, Europa Baby, Bonavita, Graco and Serta brands, consist primarily of cribs, mattresses and other nursery furniture. Sassy products, which are marketed primarily under the Sassy, Carter��, Garanimals and Kokopax brands, consist primarily of developmental toys and feeding, bath and baby care items and baby gear with features that address the various stages of an infant�� early years. The Company has five product categories: Hard Good Basics, Soft Good Basics, Toys and Entertainment, Accessories and Decor, and Other. Hard Good Basics includes cribs and other nursery furniture, feeding, food preparation and kitchen products, baby gear and organizers. Soft Good Basics includes bedding, blankets and mattresses. Toys and Entertainment includes developmental toys, bath toys and mobiles. Accessories and Decor includes hampers, lamps, rugs and decor. Other includes all other products that do not fit in the above four categories.

Advisors' Opinion:

• [By Eric Volkman]

  Kid Brands (NYSE: KID  ) has put a new individual in the CEO chair. The man formerly occupying that position, Guy Paglinco, will depart in order to, as the company put it, "pursue other activities." His replacement is James Christl, who will also serve as senior vice president. The transition is effective immediately, although Paglinco will remain a full-time employee of Kid Brands until July 5. Following that, he will make himself available in an advisory capacity for a further six months.

Top 5 Forestry Stocks To Buy For 2015: Danieli & C Officine Meccaniche SpA (DAS)

Danieli & C Officine Meccaniche SpA is an Italy-based company primarily engaged in industrial sector. The Company designs, manufactures, sales and makes installation of machines and plants for the metallurgical industry. The Company's portfolio includes mines; pellet production plants; blast furnaces; direct reduction equipment; machinery for the treatment of scrap metal; steelworks for production of liquid steel; continuous casting machinery for blooms, billets and slabs; rolling mills for long products, seamless tubes and flat products; production lines for welded tubes and flat products; plants for secondary processing, such as peeling, rolling and drawing; forging presses and manipulators; extrusion presses for ferrous and non-ferrous metals; plants for longitudinal and transversal cutting; automation and control systems, and cranes and lifting equipment. It is also active in the production and sale of special steel for automotive, machine tools and railway industry, among others. Advisors' Opinion:

• [By GURUFOCUS]

  EMC�� products ��both hardware and software - are litearlly a geek�� wonderland alphabet soup, which include Storage Area Network (SAN), Network Attached Storage (NAS), Direct Attached Storage (DAS), Virtual SAN, All-Flash XtremIO, Atmos, Avamar, �Data Domain, Isilon, Pivotal, ViPR Software Defined Storgae, VMAX, VNX, VNXe, VPLEX, VSPEX (none of these are typos).� Information storage makes up 70% of revenues and virtualization 23% of revenues.� Products generate 55% of revenues.� Services generate 45% of revenues.� The Company�� gross profit split is approximaltey 67% data storage and 31% virtualization.

• [By Damian Illia]

  Crown Castle has acquired recently the privately held company NextG Networks Inc., largest provider of outdoor Distributed Antenna Systems (DAS), with more than 7,000 DAS plus another 1,500 nodes in the pipeline, and over 4,600 miles fiber-optic cable�� transmission rights. Through this addition, the company has improved greatly its DAS network across 26 United States metropolitan areas. As NextG has only 1.7 tenants per network on an average and thus underutilizing its capacity, Crown Castle will increase customers with no integration and rearrangement costs. Another company�� big move was the acquisition of 9,700 wireless towers from AT&T Inc. (T) Located in the top 100 markets in the U. S. T-Mobile is likely to maintain its infrastructure in these towers for the next 10 years. On top of all, the recent conversion of business into a REIT has represented long term benefits for the company in terms of tax savings and enhancing shareholders��wealth.